Sirona Biochem Corp.

Excited to kick off by engaging in productive discussions and sharing updates with our valued partners. Looking forward to deepening our collaborations and exploring new opportunities together.

With Stonegate Healthcare's support, Howard Vericco is ready to dive into discussions at on the future of biotech and the crucial role of Sirona Biochem's breakthrough anti-aging active ingredient, GlycoProtemim.

Learn More About GlycoProtemim - https://glycoprotemim.com/

Counting down the days until ! We are excited to join industry leaders, researchers, and investors worldwide to discuss the latest advancements in cosmetic science and biotech.

Stonegate Healthcare has set up nearly 30 confirmed meetings for Sirona Biochem at the upcoming conference. Looking forward to connecting with industry peers and potential partners at the event.

https://convention.bio.org/

We are pleased to provide major updates ranging from our latest AGM to the closure of our financing round and the upcoming launch of our GlycoProteMim™ product line.

Read our full press release: https://www.globenewswire.com/news-release/2024/04/08/2858883/0/en/SIRONA-BIOCHEM-Corporate-Update-April-2024.html

Home - Sirona Biochem Advancing Chemistry, Enhancing Health Our proprietary platform enables us to develop safer and more effective active ingredients for next-generation medical products and treatments. Our disruptive patented compounds are licensed by pharmaceutical companies worldwide. Download our latest Investor Pre...

Sirona Biochem officially marks its 15th year on the TSX Venture Exchange. Thank you to all our investors and supporters for joining us on this journey. To many more years of scientific advancements and innovation.

Sirona Biochem's Chief Scientific Officer, Dr. Géraldine Deliencourt-Godefroy, shares insights on the planned commercialization of GlycoProteMim™ through Sirona Laboratories in an exclusive interview with the Investing News Network.

Watch the full interview below. https://i.mtr.cool/lbdcfvkxlo

Sirona Biochem eyes commercialization of breakthrough anti-aging compound Sirona Biochem’s (TSXV:SBM) chief scientific officer Géraldine Deliencourt-Godefroy provides an update on the progress of its breakthrough anti-aging compoun...

We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem's path forward.

Read more: bit.ly/sironabiochemjan24

Sirona Biochem Corp. is proud to introduce Sirona Laboratories™ – a wholly-owned subsidiary dedicated to maximizing the commercial potential of its breakthrough anti-aging skincare ingredient, GlycoProteMim™.

Read more: https://i.mtr.cool/nkymiycmgj

Wishing you all a Happy New Year! Exciting ventures lie ahead for us in 2024. The New Year brings with it a wave of new innovations and opportunities. Here's to a year filled with success and limitless possibilities!

Real Results in 12 Weeks. From reduced wrinkles to reshaped contours, see the visible impact of GlycoProteMim™ on aging skin.

GlycoProteMim™ Advantage: Reverse Skin Aging, Safely and Effectively. Clinically proven for all skin types, this topical solution delivers unparalleled anti-aging benefits without invasive procedures or harmful side effects.

GlycoProteMim™ is paving a new era in anti-aging science, offering superior efficacy and safety compared to other outdated treatments.

Today, we proudly announce the trademarking of our groundbreaking anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim™. Sirona Biochem is now engaging industry experts to chart the most effective course for commercializing GlycoProteMim™.

Read article to learn more: https://mtr.cool/ehyzvhbmxo

The 25th World Congress of Dermatology in Singapore brought together the world’s leading dermatologists, scientists, and researchers. There it was addressed that pigmentary disorders affect many people globally, which is in line with our work – TFC-1067:

“Research from L’Oréal’s La Roche-Posay found 50% of women globally suffer from self-reported pigmentary disorders (PD). These include vitiligo, post-inflammatory hyperpigmentation and melasma.”

Find out more: https://www.cosmeticsbusiness.com/news/article_page/Game_changing_skin_science_from_the_25th_World_Congress_of_Dermatology/209976

Game changing skin science from the 25th World Congress of Dermatology From period skin to microneedle serum, we round-up newness from the world of dermatology

We are pleased to provide a corporate update on the progress we have made over the last months, including our corporate strategic planning and different compounds. Learn more here: https://www.sironabiochem.com/sirona-biochem-corporate-update

Sirona Biochem Corporate Update - Sirona Biochem Vancouver, Canada – July 13, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update: Dear shareholders, We are pleased to provide an update on the progress we have made over the last months: Corporate Strategic Planning One of our communicat...

🇨🇦🚫🐇The Government of Canada, led by Health Minister Jean-Yves Duclos, has announced a ban on animal testing for cosmetic products in the country. Our compounds TFC-1067 and TFC-1326 have always been free of animal testing and we are pleased with the governmental development in support of cruelty-free cosmetics.

Further, Health Canada is actively collaborating with international scientific and regulatory bodies to develop and implement effective alternatives to animal testing, extending beyond cosmetics:

Canadian Government Officially Bans Animal Testing for Cosmetics Products The Honorable Jean-Yves Duclos, minister of health, announced that the Government of Canada has banned the cruel and unnecessary testing of cosmetic products on animals in Canada.

Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB (International Centre for Genetic Engineering and Biotechnology)
https://www.sironabiochem.com/sirona-biochem-advances-antiviral-research-with-new-compound-candidates-for-testing-at-the-icgeb/

Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB - Sirona Biochem Vancouver, Canada – June 28, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona“) is excited to announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and ...

📈📣 Novartis, one of the leading pharmaceutical giants, has acquired Vancouver based biotech firm Chinook in a deal valued up to $3.5 billion! 🌟 This moment marks a significant milestone for their exceptional contributions to the field of kidney disease treatments and research. Further, their acquisition is a testament to the expertise and dedication of North American biotech companies.

We applaud their remarkable progress and look forward to the transformative impact they will continue to make.

Novartis inks $3.2B Chinook buyout to lift kidney disease plans Novartis wants to give a $3.2 billion lift to its kidney disease pipeline. | Novartis wants to give a $3.2 billion lift to its kidney disease pipeline. While working to generate phase 3 data on its own IgA nephropathy candidate, the Swiss drugmaker has seized the chance to buy Chinook Therapeutics f...

Thank you for providing a way to showcase our innovative projects and foster meaningful connections within the industry! Our anti-aging project earned much attention thanks to the presentation by Dr. Géraldine Deliencourt-Godefroy and we had many successful meetings that brought exposure to all our projects. We had a great conference and look forward to continuing the discussions with potential partners and companies.

BIO International Convention Biotechnology Innovation Organization - BIO